Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortés J, Baselga J, Perou CM, Prat A, Rubio IT, Arribas J.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju291. doi: 10.1093/jnci/dju291. Print 2014 Nov.

2.

Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.

Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, Arribas J.

Cancer Res. 2013 Jan 1;73(1):450-8. doi: 10.1158/0008-5472.CAN-12-2301. Erratum in: Cancer Res. 2013 Oct 1;73(19):6095.

3.

A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers.

Morancho B, Parra-Palau JL, Ibrahim YH, Bernadó Morales C, Peg V, Bech-Serra JJ, Pandiella A, Canals F, Baselga J, Rubio I, Arribas J.

Oncogene. 2013 Mar 14;32(11):1452-9. doi: 10.1038/onc.2012.152. Epub 2012 May 28.

PMID:
22641219
4.

p95HER2 and breast cancer.

Arribas J, Baselga J, Pedersen K, Parra-Palau JL.

Cancer Res. 2011 Mar 1;71(5):1515-9. doi: 10.1158/0008-5472.CAN-10-3795. Epub 2011 Feb 22. Review.

5.

A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.

Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M, Mancilla S, Sánchez Pla A, Ramón Y Cajal S, Baselga J, Arribas J.

Cancer Res. 2010 Nov 1;70(21):8537-46. doi: 10.1158/0008-5472.CAN-10-1701. Epub 2010 Oct 26.

6.

HER2 fragmentation and breast cancer stratification.

Arribas J, Parra-Palau JL, Pedersen K.

Clin Cancer Res. 2010 Aug 15;16(16):4071-3. doi: 10.1158/1078-0432.CCR-10-1501. Epub 2010 Aug 3. Review.

7.

HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation.

García-Castillo J, Pedersen K, Angelini PD, Bech-Serra JJ, Colomé N, Cunningham MP, Parra-Palau JL, Canals F, Baselga J, Arribas J.

J Biol Chem. 2009 Sep 11;284(37):25302-13. doi: 10.1074/jbc.M109.001982. Epub 2009 Jul 8.

8.

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.

Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramón C, Luque-García A, García-Castillo J, Parra-Palau JL, Scaltriti M, Ramón y Cajal S, Baselga J, Arribas J.

Mol Cell Biol. 2009 Jun;29(12):3319-31. doi: 10.1128/MCB.01803-08. Epub 2009 Apr 13.

9.

The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases).

Buxade M, Parra-Palau JL, Proud CG.

Front Biosci. 2008 May 1;13:5359-73. Review.

PMID:
18508592
10.

The Drosophila protein kinase LK6 is regulated by ERK and phosphorylates the eukaryotic initiation factor eIF4E in vivo.

Parra-Palau JL, Scheper GC, Harper DE, Proud CG.

Biochem J. 2005 Feb 1;385(Pt 3):695-702.

11.

Features in the N and C termini of the MAPK-interacting kinase Mnk1 mediate its nucleocytoplasmic shuttling.

Parra-Palau JL, Scheper GC, Wilson ML, Proud CG.

J Biol Chem. 2003 Nov 7;278(45):44197-204. Epub 2003 Aug 28.

Supplemental Content

Loading ...
Support Center